IMMUNITYBIO, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-12: Study NCT07217496; Company role Lead sponsor; Phase Phase 1; Status Not yet recruiting.
- 2026-11-30: Study NCT07756593; Company role Collaborator; Phase Phase 1; Status Not yet recruiting.
- 2026-10-15: Study NCT07783789; Company role Lead sponsor; Phase Phase 2; Status Not yet recruiting.
- 2026-09-01: Study NCT07488884; Company role Lead sponsor; Phase Phase 1; Status Withdrawn.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-12 | NCT07217496 N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer | Lead sponsor | Phase 1 | Not yet recruiting | Metastatic Urothelial Carcinoma; Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma; Urothelial Cancer; Bladder Cancer | 18 | 2032-01 |
| 2026-11-30 | NCT07756593 Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer | Collaborator Lead: Washington University School of Medicine | Phase 1 | Not yet recruiting | Prostate Cancer; Metastatic Prostate Cancer | 30 | 2031-01-31 |
| 2026-10-15 | NCT07783789 NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis | Lead sponsor | Phase 2 | Not yet recruiting | Sepsis | 50 | 2028-08-13 |
| 2026-09-01 | NCT07488884 Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer | Lead sponsor | Phase 1 | Withdrawn | Pancreatic Cancer Resectable; Pancreatic Cancer | 0 | 2029-06-01 |
| 2026-07-22 | NCT07628062 Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation | Lead sponsor | Phase 2 | Not yet recruiting | HPV-Positive Oropharyngeal Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Head and Neck Cancer | 70 | 2031-06-27 |
| 2026-07-07 | NCT07355205 First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | Collaborator Lead: Washington University School of Medicine | Phase 1, Phase 2 | Recruiting | Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent | 26 | 2032-07-31 |
| 2026-07-06 | NCT07578558 NAI for Sepsis With Persistent Lymphopenia | Lead sponsor | Phase 2 | Not yet recruiting | Sepsis; Septic Shock; Lymphopenia; Immunosuppression; Critical Illness | 50 | 2027-10-04 |
| 2026-05-29 | NCT07524257 Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC | Lead sponsor | Phase 3 | Withdrawn | NSCLC (Advanced Non-small Cell Lung Cancer); Metastatic NSCLC | 0 | 2029-12-30 |
| 2026-05-15 | NCT07551544 ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer | Lead sponsor | Phase 3 | Withdrawn | NMIBC | 0 | 2032-05 |
| 2026-04-15 | NCT07492888 Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) | Lead sponsor | Phase 2 | Withdrawn | Acute Respiratory Distress Syndrome; Severe Community-Acquired Pneum; Sepsis; Lymphopenia / Immunoparalysis in Critically Ill Adults | 0 | 2027-01-15 |
| 2026-04-15 | NCT07492875 Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia | Lead sponsor | Phase 3 | Withdrawn | Community-Acquired Pneumonia (CAP); Acute Respiratory Distress Syndrome (ARDS); Sepsis; Lymphopenia; Immunoparalysis | 0 | 2029-12-31 |
| 2026-04 | NCT07477366 Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma | Lead sponsor | Phase 2 | Not yet recruiting | Relapsed B-Cell Non-Hodgkin Lymphoma | 20 | 2028-12 |
| 2026-02 | NCT07049432 N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas | Collaborator Lead: University of Utah | Phase 1 | Withdrawn | B-cell Non Hodgkin Lymphoma | 0 | 2031-12 |
| 2025-12-15 | NCT06765902 Immunotherapy Before and After Surgery | Lead sponsor | Phase 2 | Withdrawn | High-risk Prostate Cancer | 0 | 2031-06-30 |
| 2025-12-01 | NCT06765954 Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. | Lead sponsor | Phase 2 | Withdrawn | High-risk Prostate Cancer | 0 | 2031-06-30 |
| 2025-11-14 | NCT07108036 A Study to Assess Anktiva in Patients With Long Covid-19. | Lead sponsor | Phase 2 | Recruiting | Long COVID | 20 | 2026-10 |
| 2025-11-11 | NCT07125872 Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma | Lead sponsor | Phase 2 | Recruiting | Relapsed B-Cell Non Hodgkin Lymphoma | 20 | 2028-05-25 |
| 2025-11 | NCT06829823 Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | Lead sponsor | Phase 2 | Not yet recruiting | Non-muscle Invasive Bladder Cancer (NMIBC) | 20 | 2029-11 |
| 2025-10-15 | NCT06800963 ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG | Lead sponsor | Phase 1, Phase 2 | Recruiting | NMIBC | 40 | 2028-02 |
| 2025-10-01 | NCT06745908 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In | Lead sponsor | Phase 3 | Recruiting | NSCLC Stage IV | 507 | 2029-01 |
| 2025-09-04 | NCT07123727 A Study to Examine Anktiva for the Treatment of COVID-19. | Lead sponsor | Phase 2 | Recruiting | Long COVID; Long COVID Syndrome; Long Covid 19 | 40 | 2027-03 |
| 2025-08-22 | NCT05618925 Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma | Lead sponsor | Phase 1 | Recruiting | Non Hodgkin's Lymphoma Refractory/Relapsed | 20 | 2027-03-15 |
| 2025-04-11 | NCT07556757 A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia | Lead sponsor | Phase 1 | Terminated | B-ALL; Leukemia | 4 | 2026-07-01 |
| 2024-11-06 | NCT06710288 A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer | Lead sponsor | Phase 2 | Recruiting | Platinum-resistant Ovarian Cancer | 20 | 2027-05 |
| 2024-08-23 | NCT06334991 Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma | Lead sponsor | Phase 1 | Active not recruiting | Non-Hodgkin Lymphoma Refractory/ Relapsed | 20 | 2027-10 |
| 2024-08-07 | NCT06061809 N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | Lead sponsor | Phase 2 | Active not recruiting | Glioblastoma | 34 | 2030-12-31 |
| 2024-06-14 | NCT05976828 IBRX-042 In Participants With HPV-Associated Tumors | Lead sponsor | Phase 1 | Active not recruiting | HPV-Related Carcinoma | 12 | 2033-08-14 |
| 2024-02-16 | NCT06239220 PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | Collaborator Lead: Dana-Farber Cancer Institute | Phase 2 | Recruiting | Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer; Metastatic Head-and-neck Squamous-cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma | 25 | 2027-03-31 |
| 2023-10-04 | NCT06040918 Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis | Lead sponsor | Phase 1 | Completed | Healthy Subjects | 10 | 2024-09-03 |
| 2023-08-17 | NCT05981131 Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC) | Lead sponsor | Observational | Active not recruiting | Non Muscle Invasive Bladder Cancer | 6 | 2033-08-30 |
| 2022-10-17 | NCT05304936 HCW9218 for Advanced Pancreatic Cancer | Lead sponsor | Phase 1, Phase 2 | Completed | Advanced Pancreatic Carcinoma | 21 | 2025-02-15 |
| 2022-05-05 | NCT05370040 THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | COVID-19 | 60 | 2024-03-11 |
| 2021-12 | NCT04845191 COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Covid19 | 0 | 2021-12-14 |
| 2021-12 | NCT04843722 COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Covid19 | 0 | 2021-12-14 |
| 2021-10-31 | NCT05007769 Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC | Collaborator Lead: Washington University School of Medicine | Phase 2 | Withdrawn | Non-small Cell Lung Cancer; Non-small Cell Carcinoma; NSCLC; Non Small Cell Lung Cancer | 0 | 2026-04-30 |
| 2021-09-08 | NCT04927884 A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Advanced Triple Negative Breast Cancer | 3 | 2022-12-12 |
| 2021-06-21 | NCT04898543 QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors | Lead sponsor | Phase 1 | Active not recruiting | Metastatic Solid Tumor | 50 | 2026-05-31 |
| 2021-05-21 | NCT04340596 Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption | Collaborator Lead: National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | Active not recruiting | HIV Infection | 118 | 2026-12-30 |
| 2021-03-02 | NCT04710303 COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults | Lead sponsor | Phase 1 | Completed Results posted | Covid19 | 41 | 2022-08-02 |
| 2021-02-24 | NCT04732468 COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA | Lead sponsor | Phase 1 | Terminated Results posted | Covid19 | 28 | 2023-01-09 |
| 2020-12-09 | NCT06022224 A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL | Lead sponsor | Phase 2, Phase 3 | Terminated Results posted | COVID-19 | 35 | 2023-07-19 |
| 2020-10-19 | NCT04591717 COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers | Lead sponsor | Phase 1 | Completed | COVID-19 | 34 | 2023-01-18 |
| 2020-08-03 | NCT04397796 Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation | Lead sponsor | Phase 1 | Terminated Results posted | COVID | 4 | 2020-09-06 |
| 2020-07-22 | NCT04385849 Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19 | Lead sponsor | Phase 1 | Terminated Results posted | COVID-19 | 1 | 2020-07-25 |
| 2020-07-21 | NCT04390399 Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | Lead sponsor | Phase 2 | Active not recruiting | Pancreatic Cancer | 328 | 2026-05-31 |
| 2020-02-19 | NCT03853317 QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy | Lead sponsor | Phase 2 | Terminated Results posted | Merkel Cell Carcinoma | 9 | 2022-09-19 |
| 2019-09-16 | NCT04052061 QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma | Lead sponsor | Phase 1 | Withdrawn | Diffuse Large B Cell Lymphoma; Large-cell Lymphoma; Lymphoma, B-Cell; Lymphoma | 0 | 2022-08-19 |
| 2019-07-18 | NCT04050709 QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers | Lead sponsor | Phase 1 | Completed | Locally Advanced Solid Tumor; Metastatic Cancer; Solid Tumor | 16 | 2026-03-25 |
| 2018-12-11 | NCT03228667 QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | Lead sponsor | Phase 2 | Active not recruiting | Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Urothelial Carcinoma; Head and Neck Squamous Cell Carcinoma; Merkel Cell Carcinoma; Melanoma; Renal Cell Carcinoma; Gastric Cancer; Cervical Cancer; Hepatocellular Carcinoma; Microsatellite Instability; Mismatch Repair Deficiency; Colorectal Cancer | 40 | 2030-12-31 |
| 2018-09-28 | NCT03563157 QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Colorectal Cancer Metastatic; mCRC | 2 | 2019-08-21 |
| 2018-09 | NCT03554109 QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | Lead sponsor | Phase 2 | Withdrawn | Triple Negative Breast Cancer (TNBC) | 0 | 2022-02-09 |
| 2018-08-31 | NCT03647423 QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Chordoma; Unresectable Malignant Neoplasm | 0 | 2021-12-28 |
| 2018-08 | NCT03563144 QUILT-3.088: NANT Pancreatic Cancer Vaccine | Lead sponsor | Phase 2 | Withdrawn | Metastatic Pancreatic Cancer | 0 | 2022-02-09 |
| 2018-08 | NCT03169777 QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Colorectal Cancer | 0 | 2021-12-28 |
| 2018-07-17 | NCT03586869 QUILT-3.080: NANT Pancreatic Cancer Vaccine | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Pancreatic Cancer | 3 | 2019-08-01 |
| 2018-06 | NCT03574649 QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | Lead sponsor | Phase 2 | Withdrawn | Non Small Cell Lung Cancer | 0 | 2018-08-22 |
| 2018-05-25 | NCT03563170 QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Hepatocellular Carcinoma Non-resectable; Hepatocellular Carcinoma Recurrent | 0 | 2019-08-23 |
| 2018-05-18 | NCT03520686 Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | Lead sponsor | Phase 3 | Terminated | Non Small Cell Lung Cancer | 102 | 2025-10-13 |
| 2018-03-19 | NCT03387085 QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Triple Negative Breast Cancer | 9 | 2024-01-16 |
| 2018-02 | NCT03169738 QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Non-small Cell Lung Cancer | 0 | 2021-12-28 |
| 2018-01-09 | NCT03387111 QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Squamous Cell Carcinoma | 4 | 2021-01-11 |
| 2017-12-28 | NCT03387098 QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Pancreatic Cancer | 4 | 2019-01-15 |
| 2017-12 | NCT03197584 QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Ovarian Cancer | 0 | 2021-12-28 |
| 2017-12 | NCT03197571 QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Urothelial Carcinoma | 0 | 2021-12-28 |
| 2017-12 | NCT03175666 QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Triple Negative Breast Cancer | 0 | 2021-12-28 |
| 2017-12 | NCT03169790 QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Non Hodgkin Lymphoma | 0 | 2021-12-23 |
| 2017-12 | NCT03169764 QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Head and Neck Squamous Cell Carcinoma | 0 | 2021-12-28 |
| 2017-12 | NCT03167177 QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Melanoma | 0 | 2021-12-28 |
| 2017-12 | NCT03167164 QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy | Lead sponsor | Phase 1, Phase 2 | Withdrawn | Merkel Cell Carcinoma | 0 | 2021-12-28 |
| 2017-11-21 | NCT03317158 Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder | Collaborator Lead: Noah Hahn, M.D. | Phase 1, Phase 2 | Active not recruiting | Urothelial Carcinoma; Bladder Cancer | 186 | 2029-12-31 |
| 2017-11-06 | NCT03329248 QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Pancreatic Cancer | 6 | 2019-11-01 |
| 2017-08-11 | NCT03136406 QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Pancreatic Cancer | 3 | 2019-11-01 |
| 2017-08-02 | NCT03027128 QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors | Lead sponsor | Phase 1 | Completed Results posted | Solid Tumor | 6 | 2019-05-06 |
| 2017-06-02 | NCT03022825 QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer | Lead sponsor | Phase 2, Phase 3 | Active not recruiting | Bladder Cancer | 190 | 2029-03-01 |
| 2017-01-30 | NCT02782546 Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation | Collaborator Lead: Washington University School of Medicine | Phase 2 | Active not recruiting Results posted | Acute Myeloid Leukemia | 60 | 2028-02-13 |
| 2015-09-24 | NCT02465957 QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) | Lead sponsor | Phase 2 | Terminated Results posted | Stage IIIB Merkel Cell Carcinoma; Stage IV Merkel Cell Carcinoma | 7 | 2018-03-19 |
| 2015-04-20 | NCT02200757 Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer | Lead sponsor | Phase 2 | Completed Results posted | Metastatic Small Cell Lung Cancer | 135 | 2017-05-15 |
| 2014-09-02 | NCT02235701 Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma | Lead sponsor | Phase 1, Phase 2 | Completed Results posted | Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma | 70 | 2018-05-01 |
| 2014-08-11 | NCT01898793 Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Collaborator Lead: Washington University School of Medicine | Phase 1, Phase 2 | Terminated Results posted | Leukemia, Myeloid, Acute | 89 | 2022-04-04 |
| 2014-08 | NCT02235688 Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors | Lead sponsor | Phase 1 | Completed | Metastatic Solid Tumors | 30 | 2017-01 |
| 2014-07-21 | NCT02138734 A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | Lead sponsor | Phase 1, Phase 2 | Active not recruiting | Non-muscle Invasive Bladder Cancer | 369 | 2039-03-04 |
| 2014-05-12 | NCT00900809 QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia | Lead sponsor | Phase 1 | Completed | Acute Myeloid Leukemia | 7 | 2015-06-02 |
| 2014-04-03 | NCT02029430 A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma | Lead sponsor | Phase 2 | Completed Results posted | Kaposi's Sarcoma; HIV Positive; AIDS | 15 | 2016-04-25 |
| 2014-03 | NCT02014844 Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma | Lead sponsor | Phase 2 | Completed Results posted | Glioblastoma | 28 | 2016-12 |
| 2014-01 | NCT02049905 Phase 3 Study to Treat Patients With Soft Tissue Sarcomas | Lead sponsor | Phase 3 | Completed Results posted | Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma | 433 | 2017-05 |
| 2012-10 | NCT01706835 Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors | Lead sponsor | Phase 1 | Completed | Advanced Solid Tumors | 18 | 2014-12 |
| 2012-07 | NCT01673438 Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors | Lead sponsor | Phase 1 | Completed | Advanced Solid Tumor | 15 | 2014-04 |
| 2012-05-16 | NCT01580397 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer | Lead sponsor | Phase 2 | Completed Results posted | Pancreatic Ductal Adenocarcinoma | 15 | 2013-07-02 |
| 2012-01-11 | NCT01514188 Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma | Lead sponsor | Phase 2 | Completed Results posted | Metastatic Soft Tissue Sarcoma; Locally Advanced Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma | 126 | 2014-12-15 |
| 2011-04 | NCT01337505 Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors | Lead sponsor | Phase 1 | Completed | Malignant Solid Tumour | 24 | 2012-12 |
| NCT06956547 Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy | Lead sponsor | Expanded_access | Available | Lymphopenia | |||
| NCT06810141 ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer | Lead sponsor | Expanded_access | Available | NMIBC |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |